Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a clinical-stage biopharmaceutical company pioneering treatments for aggressive central nervous system cancers. This page provides investors and medical stakeholders with timely updates on the company’s groundbreaking therapies, including Berubicin for glioblastoma and TPI 287 for advanced CNS tumors.
Access consolidated updates on clinical trial progress, FDA designations, and strategic partnerships. Our news feed covers critical developments in the company’s pipeline, including Phase II results for Berubicin – the first anthracycline to cross the blood-brain barrier – and preclinical advancements for TPI 287’s microtubule-stabilizing mechanism.
Key coverage areas include regulatory milestones, peer-reviewed research publications, and collaborations with leading institutions like MD Anderson Cancer Center. Bookmark this page for verified updates on CNS Pharmaceuticals’ efforts to address unmet needs in neuro-oncology through innovative science and targeted drug development.
CNS Pharmaceuticals (NASDAQ:CNSP) announced a CEO transition: John Climaco has stepped down and Rami Levin, MBA, will become President & Chief Executive Officer effective January 1, 2026. Levin brings nearly 30 years of global biopharma experience across oncology, neurology, rare diseases, and cell & gene therapy and highlights include scaling organizations, raising capital, and advancing late‑stage programs. The release cites Levin's prior roles at Saniona, ImStem, Sobi, Merck Serono and a record of growing Sobi North American revenue from $46M to >$500M. CNS expects Levin to advance TPI 287 and strengthen commercial and development strategy.
CNS Pharmaceuticals (NASDAQ:CNSP) reported Q3 2025 results and a corporate update on November 17, 2025. Key financials: net loss $3.3M vs $5.6M year-ago, R&D $2.2M vs $4.2M, G&A $1.1M vs $1.4M, and cash $9.9M as of September 30, 2025. Management says cash is expected to fund operations into the second half of 2026. Lead program TPI 287 — an abeotaxane engineered for blood-brain barrier penetration — showed Phase 1 activity in GBM with 3 complete responses and 9 partial responses among 23 evaluable patients. The company plans FDA engagement on a potential Phase 2/registration study in early 2026.
CNS Pharmaceuticals (NASDAQ:CNSP) announced three abstracts accepted for poster presentation at the Society for Neuro-Oncology (SNO) 30th Annual Meeting, Nov 19-23, 2025, in Honolulu, HI.
All three posters will be presented by Sandra Silberman, MD, PhD, CNS chief medical officer: preliminary activity of berubicin against pediatric diffuse midline glioma (DMG) on Nov 21, 2025; planned Phase 2 evaluation of TPI 287 plus bevacizumab and other CNS indications on Nov 22, 2025; and primary randomized trial results comparing berubicin vs lomustine in glioblastoma after prior therapy on Nov 22, 2025.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 in New York.
The company's presentation will be available via video webcast starting September 8, 2025, at 7:00 AM ET for registered attendees. Management will also conduct one-on-one meetings with qualified investors during the conference. The webcast recording will remain accessible on the company's website for 90 days after the event.
CNS Pharmaceuticals (NASDAQ:CNSP) has reported its Q2 2025 financial results and provided updates on its drug development programs. The company maintains a strong cash position of $12.1 million, expected to sustain operations into H2 2026.
The company's lead program, TPI 287, an abeotaxane designed to cross the blood-brain barrier, showed promising results in Phase 1 trials for glioblastoma multiforme (GBM), achieving 3 Complete Responses and 9 Partial Responses out of 23 evaluable patients when combined with bevacizumab. CNS plans to initiate a Phase 2 study in H1 2026 and engage with FDA on study design in 2025.
For Q2 2025, CNS reported a net loss of $2.4 million, slightly improved from $2.5 million in Q2 2024, with R&D expenses of $1.2 million and reduced G&A expenses of $1.2 million.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will participate in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. The virtual presentation will be delivered by CEO John Climaco on Tuesday, August 19, 2025, at 2:40 PM ET.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. CEO John Climaco presented at the event, sharing insights about his leadership journey and passion for the company's development programs.
The presentation is now available for viewing on virtualinvestorco.com and the Events page in the Investors section of cnspharma.com.
CNS Pharmaceuticals (NASDAQ:CNSP) has announced a 1-for-12 reverse stock split of its common stock, effective July 22, 2025. The biopharmaceutical company's stock will continue trading on the Nasdaq Capital Market under the same symbol "CNSP" but with a new CUSIP number: 18978H508.
Under this reverse split, every 12 shares will be automatically combined into one share, with proportional adjustments made to outstanding warrants and equity-based awards. The company's authorized shares will be reduced to 25 million, while maintaining a par value of $0.001 per share. Stockholders entitled to fractional shares will receive cash payments instead.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, announced CEO John Climaco's participation in a Virtual Investor CEO Connect segment. During the presentation, Climaco discussed the company's lead program TPI 287 and shared insights from the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, MA.
CNS Pharmaceuticals (NASDAQ:CNSP) has released a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital. The segment focuses on Glioblastoma Multiforme (GBM) treatment landscape and the company's lead product candidate, TPI 287.
Dr. Dunbar, who specializes in brain and spine tumor patient care, discusses the potential of TPI 287 as a treatment for GBM and its possible applications for metastatic tumors. The virtual segment is now available for viewing online.
FAQ
What is the current stock price of CNS Pharmaceuticals (CNSP)?
What is the market cap of CNS Pharmaceuticals (CNSP)?
